ADMA Biologics (ADMA) Tops Q3 EPS by 2c

ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $62.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Keurig Dr Pepper coffee chief to depart ahead of planned split